<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332266</url>
  </required_header>
  <id_info>
    <org_study_id>E7050-702</org_study_id>
    <secondary_id>2011-000773-31</secondary_id>
    <nct_id>NCT01332266</nct_id>
  </id_info>
  <brief_title>E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaBio Development Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether patients with Platinum-Resistant Squamous
      Cell Carcinoma of the Head and Neck who receive either E7050 administered with Cetuximab or
      Cetuximab alone experience greater benefit
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, multicenter, randomized study will consist of a Phase Ib: a safety run-in
      period with 3 ascending doses of E7050 in combination with Cetuximab; and a Phase II portion:
      a randomized 2-arm period. Approximately 95 patients with Platinum-Resistant Squamous Cell
      Carcinoma of the head and neck will be enrolled in the study (10-15 patients in the Phase Ib
      portion and 80 patients in the Phase II portion). Patients will only participate in either
      the Phase Ib or the Phase II portion of the study.

      In the phase II portion, Patients will receive study treatment (E7050 plus Cetuximab or
      Cetuximab alone) for approximately six 28-day cycles (24 weeks). Beyond 24 weeks, patients
      who are experiencing clinical benefit may continue E7050 plus cetuximab, cetuximab alone or
      E7050 alone (Arm 1), or may continue cetuximab alone (Arm 2), depending on the original
      randomization treatment arm, for as long as clinical benefit is sustained and the treatment
      is well tolerated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2011</start_date>
  <completion_date type="Actual">August 26, 2017</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Parameters- Adverse Events</measure>
    <time_frame>until study termination; 3 years</time_frame>
    <description>Phase Ib: to determine the MTD/recommended Phase II dose and characterize the pharmacokinetics (PK) of E7050 when administered in combination with cetuximab in patients with platinum-resistant, recurrent and/or metastatic squamous cell carcinoma for the head and neck (SCCHN).
Phase II: to evaluate the safety and tolerability of E7050 administered in combination with cetuximab compared with cetuximab alone in patients with platinum-resistant, recurrent and/or metastatic SCCHN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Parameter- concomitant medications</measure>
    <time_frame>until study termination; 3 years</time_frame>
    <description>Phase Ib: to determine the MTD/recommended Phase II dose and characterize the pharmacokinetics (PK) of E7050 when administered in combination with cetuximab in patients with platinum-resistant, recurrent and/or metastatic squamous cell carcinoma for the head and neck (SCCHN).
Phase II: to evaluate the safety and tolerability of E7050 administered in combination with cetuximab compared with cetuximab alone in patients with platinum-resistant, recurrent and/or metastatic SCCHN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Parameter- Lab tests</measure>
    <time_frame>Day 1 and every 28 days until study termination; 3 years</time_frame>
    <description>Phase Ib: to determine the MTD/recommended Phase II dose and characterize the pharmacokinetics (PK) of E7050 when administered in combination with cetuximab in patients with platinum-resistant, recurrent and/or metastatic squamous cell carcinoma for the head and neck (SCCHN).
Phase II: to evaluate the safety and tolerability of E7050 administered in combination with cetuximab compared with cetuximab alone in patients with platinum-resistant, recurrent and/or metastatic SCCHN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Parameter- ECGs</measure>
    <time_frame>Screening and 28 days after end of therapy; 3 years</time_frame>
    <description>Phase Ib: to determine the MTD/recommended Phase II dose and characterize the pharmacokinetics (PK) of E7050 when administered in combination with cetuximab in patients with platinum-resistant, recurrent and/or metastatic squamous cell carcinoma for the head and neck (SCCHN).
Phase II: to evaluate the safety and tolerability of E7050 administered in combination with cetuximab compared with cetuximab alone in patients with platinum-resistant, recurrent and/or metastatic SCCHN.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Parameter</measure>
    <time_frame>Time Frame: Time to progression (TTP)-until the date of first documented progression of such patient's disease or death for 3 years</time_frame>
    <description>Phase Ib: To determine the MTD/recommended Phase II dose and characterize the pharmacokinetics (PK) of E7050 when administered in combination with cetuximab in patients with platinum-resistant, recurrent and/or metastatic SCCHN;
Phase II: To evaluate the safety and tolerability of E7050 when administered in combination with cetuximab as compared with cetuximab alone in patients with platinum-resistant, recurrent and/or metastatic SCCHN..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Parameter</measure>
    <time_frame>Overall survival (OS)-until the date of first documented progression of such patient's disease or death for 3 years</time_frame>
    <description>Phase Ib: To determine the MTD/recommended Phase II dose and characterize the pharmacokinetics (PK) of E7050 when administered in combination with cetuximab in patients with platinum-resistant, recurrent and/or metastatic SCCHN;
Phase II: To evaluate the safety and tolerability of E7050 when administered in combination with cetuximab as compared with cetuximab alone in patients with platinum-resistant, recurrent and/or metastatic SCCHN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Parameter</measure>
    <time_frame>Overall response rate (ORR)-until the date of first documented progression of such patient's disease or death for 3 years</time_frame>
    <description>Phase Ib: To determine the MTD/recommended Phase II dose and characterize the pharmacokinetics (PK) of E7050 when administered in combination with cetuximab in patients with platinum-resistant, recurrent and/or metastatic SCCHN;
Phase II: To evaluate the safety and tolerability of E7050 when administered in combination with cetuximab as compared with cetuximab alone in patients with platinum-resistant, recurrent and/or metastatic SCCHN.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Active Comparator; Phase IB: Cohort 1,2,and 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase Ib:
Cohort 1; 200 mg E7050 + 250 mg/m2 cetuximab Cohort 2; 300 mg E7050 + 250 mg/m2 cetuximab Cohort 3; 400mg E7050 + 250mg/m2 cetuximab
Phase II: Arm 1; MTD E7050 + 250 mg cetuximab Arm 2; 250 mg cetuximab
Interventions: Drug cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase II:
Arm 1; MTD E7050 + 250 mg/m2 cetuximab Arm 2; 250 mg/m2 cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7050</intervention_name>
    <description>E7050 given orally at 200, 300, or 400 mg once daily.</description>
    <arm_group_label>Active Comparator; Phase IB: Cohort 1,2,and 3</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.</description>
    <arm_group_label>Active Comparator; Phase IB: Cohort 1,2,and 3</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Platinum-resistant (defined as failure to respond to treatment with a platinum agent
             or recurrence of disease after initial response to platinum within 12 months of
             completing therapy), locally advanced, recurrent and/or metastatic SCCHN, which is
             untreatable by surgical resection or radiation therapy;

          -  ECOG PS of 0-2;

          -  Blood pressure must be well-controlled. Patients must have no history of hypertensive
             crisis or hypertensive encephalopathy; Adequate end organ function

        Exclusion Criteria

          -  Nasopharyngeal tumors;

          -  Previously received E7050, anti-cmet, anti-angiogenic therapy, or anti-EGFR therapy
             (prior anti-angiogenic/EGFR therapy is permitted in Phase Ib only. Prior cetuximab is
             permitted if administered in combination with radiation;

          -  Presence of brain metastases, unless the patient has received adequate treatment at
             least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids
             for at least 4 weeks prior to randomization;

          -  Palliative radiotherapy is not permitted throughout the study period;

          -  Clinically significant hemoptysis;

          -  Serious non-healing wound, ulcer, or active bone fracture;

          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             prior to Day 1, or anticipation of need for a major surgical procedure during the
             course of the study;

          -  Clinically significant gastrointestinal bleeding within 6 months prior to first dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa J Versola, RN</last_name>
    <role>Study Director</role>
    <affiliation>Innovation Quintiles</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <zip>83003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <zip>3057</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumy</city>
        <zip>40005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <state>Strathclyde</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
    <country>India</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>head and neck</keyword>
  <keyword>squamous cell carcinoma of the head and neck</keyword>
  <keyword>phase I</keyword>
  <keyword>phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

